Berlin, Germany- 6th January 2011- NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, announced today that it has been invited to present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Iain Buchanan, NOXXON’s Chief Executive Officer, will give a presentation on the Company’s Spiegelmer® technology and the current status of NOXXON’s drug pipeline which includes three compounds that will enter Phase II clinical studies in 2012.
The NOXXON presentation is scheduled for Tuesday, 10th January 2012 from 07:30-8:00 AM (Pacific Standard Time). The company presentation will take place in the room “Elizabethan C/D” at the Westin St. Francis Hotel in San Francisco.
About NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, a chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics:
- NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) and is currently completing a Phase Ib study in healthy subjects and diabetics as well as a pharmacokinetic study in subjects with renal impairment. A Phase IIa study in diabetics with renal impairment is currently in preparation.
- NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of tumor invasion, metastasis and resistance to chemotherapy, has completed Phase I. Clinical Trial Applications have been submitted for Phase IIa studies in two hematological oncology indications.
- NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease, and is currently in a comprehensive single and multiple ascending dose Phase I study. Two human efficacy trials of NOX-H94 are currently in preparation.
The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.
For more information, please visit: www.noxxon.com
NOXXON Pharma AG
College Hill Life Sciences
Dr. Robert Mayer